Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training...
Intelligent Breast Cancer DiagnOsis and MonItoring Therapeutic Response Training Network
CanDoIt will show how a smart multimodal multi-physic sensor array associated with DNA oligonucleotides and their peptide nucleic acid (PNAs) analogues dedicated for liquid biopsies analysis has the potential for more accurate dia...
ver más
31/12/2027
CENTRALE LILLE INS...
Presupuesto desconocido
Líder del proyecto
CENTRALE LILLE INSTITUT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto
el día 2024-01-01
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto CanDoIt
Duración del proyecto: 47 meses
Fecha Inicio: 2024-01-01
Fecha Fin: 2027-12-31
Líder del proyecto
CENTRALE LILLE INSTITUT
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
CanDoIt will show how a smart multimodal multi-physic sensor array associated with DNA oligonucleotides and their peptide nucleic acid (PNAs) analogues dedicated for liquid biopsies analysis has the potential for more accurate diagnostic and treatment monitoring of BC through the study of cutting-edge technologies in bio/nanomaterials, sensors and transducers design, fluidics systems, and artificial intelligence. The CanDoIt objectives are to: (1) Train the excellent next generation researchers for interdisciplinary careers in basic, applied and especially translational BC research and with “raising awareness” on social issues; (2) Develop cutting-edge technologies for BC diagnosis and monitoring therapeutic response by bringing together eminent experts from both industry and academia, including engineers, computational scientists, chemists, physicists, and clinicians; (3) Pursue key biological targets through intelligent methods, all the way from early stage to preclinical and clinical investigation; (4) In addition to respond to the BC issue, the intelligent biosystems proposed will be a real technological advance (breakthrough), thanks to the association of different transducers to go towards a multimodal platform, the association of structured nanomaterials inspired by living world and an implementation of intelligent algorithms for optimal analysis; (5) Build a high-impact structure ensuring multi-level dissemination and exploitation of all results.